[31 August 2012]
Products Affected - Description
Ticlopidine tablets, Apotex
250 mg, 30 count (NDC 60505-0027-02)
250 mg, 60 count (NDC 60505-0027-04)
250 mg, 500 count (NDC 60505-0027-07)
Reason for the Shortage
- Sandoz and Major discontinued their ticlopidine presentations in December, 2009.
- Par discontinued their ticlopidine presentations in January, 2009.
- Roche (Genentech) has discontinued Ticlid.
- Apotex has an import ban on their ticlopidine presentations.
- Caraco stopped manufacturing all ticlopidine presentations in 2009.
Ticlopidine tablets, Teva
250 mg, 100 count (NDC 00093-0154-01)
Estimated Resupply Dates
Apotex is not currently marketing ticlopidine tablets, and cannot confirm whether they will manufacture this product again in the future.
August 31, 2012; June 27, 2012; April 17, 2012; February 17, 2012; January 3, 2012; December 6, 2011; October 26, 2011; August 11, 2011; June 24, 2011; May 11, 2011; March 10, 2011; January 19, 2011; November 24, 2010; October 1, 2010; August 17, 2010; August 10, 2010; July 9, 2010, University of Utah, Drug Information Service. Copyright 2012, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins